AU2001295850A1 - Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue - Google Patents

Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue

Info

Publication number
AU2001295850A1
AU2001295850A1 AU2001295850A AU9585001A AU2001295850A1 AU 2001295850 A1 AU2001295850 A1 AU 2001295850A1 AU 2001295850 A AU2001295850 A AU 2001295850A AU 9585001 A AU9585001 A AU 9585001A AU 2001295850 A1 AU2001295850 A1 AU 2001295850A1
Authority
AU
Australia
Prior art keywords
capsules
delivering
therapeutic
tissue
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001295850A
Inventor
Shimon Eckhouse
Tamar Lotan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NanoCyte Inc
Original Assignee
NanoCyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NanoCyte Inc filed Critical NanoCyte Inc
Publication of AU2001295850A1 publication Critical patent/AU2001295850A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
AU2001295850A 2000-09-28 2001-09-26 Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue Abandoned AU2001295850A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23591000P 2000-09-28 2000-09-28
US60/235,910 2000-09-28
PCT/IL2001/000908 WO2002026191A2 (en) 2000-09-28 2001-09-26 Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue

Publications (1)

Publication Number Publication Date
AU2001295850A1 true AU2001295850A1 (en) 2002-04-08

Family

ID=22887360

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001295850A Abandoned AU2001295850A1 (en) 2000-09-28 2001-09-26 Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue

Country Status (5)

Country Link
US (5) US6613344B2 (en)
EP (1) EP1379127B1 (en)
AU (1) AU2001295850A1 (en)
IL (1) IL155097A0 (en)
WO (1) WO2002026191A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070281037A9 (en) * 2000-09-28 2007-12-06 Nanocyte Inc. Sterile preparations and compositions including stinging capsules and methods of producing and using same
US7632522B2 (en) 2000-09-28 2009-12-15 Nanocyte Inc. Use of stinging cells/capsules for the delivery of active agents to keratinous substances
IL155097A0 (en) 2000-09-28 2003-10-31 Nanocyte Inc Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
US20030036242A1 (en) 2001-08-16 2003-02-20 Haining Yang Methods of forming metal-comprising materials and capacitor electrodes; and capacitor constructions
ATE394125T1 (en) 2002-03-26 2008-05-15 Nanocyte Inc NETTLE CELLS EXPRESSING AN EXOGENEOUS POLYNUCLEOTIDE ENCODING A THERAPEUTIC, DIAGNOSTIC OR COSMETIC AGENT AND METHODS, COMPOSITIONS AND DEVICES USING SUCH NETTLE CELLS OR CAPSULES DERIVED THEREOF TO DELIVER THE THERAPEUTIC, DIAGNOSTIC OR COSMETIC AGENT INTO A TISSUE BE
KR20040043703A (en) * 2002-11-16 2004-05-27 (주)라렌드몽드 Retinoid containing chemical peeling agent
FR2873695A1 (en) * 2004-07-30 2006-02-03 Palumed Sa HYBRID MOLECULES QA OR Q IS AMINOQUINOLINE AND A IS AN ANTIBIOTIC OR A RESISTANCE INHIBITOR), THEIR SYNTHESIS AND USES THEREOF AS ANTIBACTERIAL AGENT
KR100927563B1 (en) 2004-08-06 2009-11-23 오쓰까 세이야꾸 가부시키가이샤 Aromatic compounds
US20060099272A1 (en) * 2004-11-05 2006-05-11 Nanocyte Inc. Compositions and kits including dehydrated stinging capsules and methods of producing and using same
US8834862B2 (en) 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
CA2614317A1 (en) 2005-07-07 2007-01-18 Cbd Technologies Ltd. Compositions and methods comprising stinging capsules/cells for delivering a biologically active agent into a plant cell
ZA200804445B (en) 2005-12-05 2009-11-25 Otsuka Pharma Co Ltd Diarylether derivatives as antitumor agents
IL177409A0 (en) * 2006-08-10 2006-12-10 Univ Ramot Method and apparatus for propagating benthic marine invertebrates
UA95978C2 (en) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Stat3/5 activation inhibitor
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
WO2012056452A2 (en) 2010-10-27 2012-05-03 Nanocyte (Israel) Ltd. Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
RU2016133040A (en) 2014-01-10 2018-02-14 ЧАМБЕР ВОРКС, ЭлЭлСи PERSONALIZING SUBSTANCE FOR APPLICATION TO SKIN OR ADDITION TO TATTOO INK AND METHODS FOR PRODUCING IT
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
MX2020006424A (en) 2017-12-20 2021-01-08 Allergan Inc Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation.

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US601967A (en) * 1898-04-05 Hydrant
US3321188A (en) 1965-10-04 1967-05-23 Broadway Imp S Paint mixing device
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4224013A (en) 1978-12-04 1980-09-23 Davis Sr Arthur Automobile vacuum system for inflating tires
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5459047A (en) * 1986-07-01 1995-10-17 Genetics Institute, Inc. BMP-6 proteins
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5073488A (en) 1988-11-29 1991-12-17 Minnesota Mining And Manufacturing Company Rapid method for determining efficacy of a sterilization cycle and rapid read-out biological indicator
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5162378A (en) 1990-04-20 1992-11-10 Revlon Consumer Products Corporation Silicone containing water-in-oil microemulsions having increased salt content
US5885260A (en) 1991-05-30 1999-03-23 Mehl, Sr.; Thomas L. Freeze-dried liposome delivery system for application of skin treatment agents
US5641508A (en) 1994-01-13 1997-06-24 Anticancer, Inc. Method for delivering melanin to hair follicles
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5362442A (en) 1993-07-22 1994-11-08 2920913 Canada Inc. Method for sterilizing products with gamma radiation
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
FR2729855A1 (en) 1995-01-26 1996-08-02 Oreal USE OF A CGRP ANTAGONIST IN A COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITION AND COMPOSITION OBTAINED
US6163344A (en) * 1995-08-31 2000-12-19 Nikon Corporation Electronic camera that transfers signals to an external device
US6416960B1 (en) * 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
JPH1078111A (en) * 1996-09-03 1998-03-24 Toyota Motor Corp Power transmission
ES2289192T3 (en) 1996-12-31 2008-02-01 Altea Therapeutics Corporation TISSUE MICROPORATION FOR SUPPLY OF BIOACTIVE AGENTS.
US6338837B1 (en) * 1997-05-29 2002-01-15 Nidaria Technology Ltd. Compositions and methods for inhibiting nematocyst discharge
US6132747A (en) * 1997-05-29 2000-10-17 Nidaria Technology Ltd. Compositions and methods for inhibiting nematocyst discharge
US6406709B1 (en) * 1997-05-29 2002-06-18 Nidaria Technology Ltd. Method for inhibiting nematocyst discharge
US6022316A (en) 1998-03-06 2000-02-08 Spectrx, Inc. Apparatus and method for electroporation of microporated tissue for enhancing flux rates for monitoring and delivery applications
EP1059938A1 (en) 1998-03-06 2000-12-20 Spectrx, Inc. Photothermal structure for biomedical applications, and method therefor
US6173202B1 (en) 1998-03-06 2001-01-09 Spectrx, Inc. Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue
US6630001B2 (en) 1998-06-24 2003-10-07 International Heart Institute Of Montana Foundation Compliant dehyrated tissue for implantation and process of making the same
US6352506B1 (en) 1998-07-14 2002-03-05 Altea Technologies Controlled removal of biological membrane by pyrotechnic charge for transmembrane transport
BR9912333A (en) 1998-07-21 2001-04-17 Spectrx Inc System to continuously monitor a characteristic of a biological fluid extracted from an organism and a process to extract a biological fluid from a biological membrane of an organism and continuously monitor a characteristic of it.
ATE318103T1 (en) 1998-07-21 2006-03-15 Spectrx Inc DEVICE FOR CONTINUOUS EXTRACTION AND ANALYSIS OF LIQUIDS
EP1112021A1 (en) 1998-09-10 2001-07-04 Spectrx, Inc. Attribute compensation for analyte detection and/or continuous monitoring
AU1728701A (en) 1999-11-29 2001-06-04 Nidaria Technology Ltd. A composition and method for inhibiting polar capsule discharge and protecting asubject from nematocyst sting
WO2001078504A2 (en) 2000-04-17 2001-10-25 Organ Recovery Systems, Inc. Novel warming method of cryopreserved specimens
IL155097A0 (en) * 2000-09-28 2003-10-31 Nanocyte Inc Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US20070281037A9 (en) 2000-09-28 2007-12-06 Nanocyte Inc. Sterile preparations and compositions including stinging capsules and methods of producing and using same
US7632522B2 (en) 2000-09-28 2009-12-15 Nanocyte Inc. Use of stinging cells/capsules for the delivery of active agents to keratinous substances
ATE394125T1 (en) 2002-03-26 2008-05-15 Nanocyte Inc NETTLE CELLS EXPRESSING AN EXOGENEOUS POLYNUCLEOTIDE ENCODING A THERAPEUTIC, DIAGNOSTIC OR COSMETIC AGENT AND METHODS, COMPOSITIONS AND DEVICES USING SUCH NETTLE CELLS OR CAPSULES DERIVED THEREOF TO DELIVER THE THERAPEUTIC, DIAGNOSTIC OR COSMETIC AGENT INTO A TISSUE BE
US20030189850A1 (en) 2002-04-09 2003-10-09 Toyo Boseki Kabushiki Kaisha Cell array system
JP2004344036A (en) 2003-05-21 2004-12-09 Fujitsu Ltd Substance-transducing device and substance-transducing system
US20050181978A1 (en) 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
US20060099272A1 (en) 2004-11-05 2006-05-11 Nanocyte Inc. Compositions and kits including dehydrated stinging capsules and methods of producing and using same
US8834862B2 (en) 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent

Also Published As

Publication number Publication date
US6613344B2 (en) 2003-09-02
WO2002026191A3 (en) 2003-11-20
US8062660B2 (en) 2011-11-22
US20060159769A1 (en) 2006-07-20
US20110070224A1 (en) 2011-03-24
EP1379127B1 (en) 2013-04-17
US20030202995A1 (en) 2003-10-30
US7338665B2 (en) 2008-03-04
EP1379127A4 (en) 2007-03-07
US6923976B2 (en) 2005-08-02
EP1379127A2 (en) 2004-01-14
US20020039592A1 (en) 2002-04-04
IL155097A0 (en) 2003-10-31
WO2002026191A2 (en) 2002-04-04
US8486441B2 (en) 2013-07-16
US20040224013A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
AU2001295850A1 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
IL156399A (en) Use of a modified erythropoietin for the preparation of medicaments for the protection, restoration and enhancement of erythropoietin-responsive cells, tissues and organs
AU2002241534A1 (en) Disposable aerosol generator system and methods for administering the aerosol
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
HUP0204081A3 (en) 4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
AU2001282267A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
AU5181200A (en) Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
AU5326100A (en) Pharmaceutical compositions and methods for use
AU2001266338A1 (en) Pharmaceutical compositions for angiogenic therapy
HUP0200386A3 (en) Nitroxyderivatives having antiinflammatory, analgesic and antithrombotic activity and pharmaceutical compositions containing them and their use
HUP0203194A3 (en) Phenylpiperazines, pharmaceutical compositions containing them and their use
AU2002306613A1 (en) Anhydrous antiperspirant and deodorant compositions containing a solid, water-soluble, skin active agent
AU2922600A (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
HUP0203735A3 (en) 4-pyridinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
AU2001248215A1 (en) Cosmetically active composition
AU1164601A (en) Therapeutic use and formulation
AU5117400A (en) Tip structures, devices on their basis, and methods for their preparation
HRP20010937B1 (en) Streptogramin derivatives, preparation and compositions containing them
AU2001277738A1 (en) Piperidine derivatives and drugs containing these derivatives as the active ingredient
AU5587800A (en) S-(+)-desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
HUP0200729A3 (en) Hydroxamic acid derivatives, their use and preparation and pharmaceutical compositions containing them
AU2001231964A1 (en) Device for applying active principles for pharmaceutical or cosmetic purposes
IL199236A0 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof
AU4884701A (en) Malonanilic acid derivatives, medicinal compositions containing the same and usethereof